↓ Skip to main content

Stem cells: a new paradigm for disease modeling and developing therapies for age-related macular degeneration

Overview of attention for article published in Journal of Translational Medicine, March 2013
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (70th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

twitter
2 X users
googleplus
2 Google+ users

Citations

dimensions_citation
29 Dimensions

Readers on

mendeley
94 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Stem cells: a new paradigm for disease modeling and developing therapies for age-related macular degeneration
Published in
Journal of Translational Medicine, March 2013
DOI 10.1186/1479-5876-11-53
Pubmed ID
Authors

Heather Melville, Matthew Carpiniello, Kia Hollis, Andrew Staffaroni, Nady Golestaneh

Abstract

Age-related macular degeneration (AMD) is the leading cause of blindness in people over age 55 in the U.S. and the developed world. This condition leads to the progressive impairment of central visual acuity. There are significant limitations in the understanding of disease progression in AMD as well as a lack of effective methods of treatment. Lately, there has been considerable enthusiasm for application of stem cell biology for both disease modeling and therapeutic application. Human embryonic stem cells and induced pluripotent stem cells (iPSCs) have been used in cell culture assays and in vivo animal models. Recently a clinical trial was approved by FDA to investigate the safety and efficacy of the human embryonic stem cell-derived retinal pigment epithelium (RPE) transplantation in sub-retinal space of patients with dry AMD These studies suggest that stem cell research may provide both insight regarding disease development and progression, as well as direction for therapeutic innovation for the millions of patients afflicted with AMD.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 94 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Peru 1 1%
South Africa 1 1%
Canada 1 1%
Unknown 91 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 20 21%
Student > Bachelor 20 21%
Student > Master 14 15%
Student > Ph. D. Student 9 10%
Student > Postgraduate 6 6%
Other 14 15%
Unknown 11 12%
Readers by discipline Count As %
Agricultural and Biological Sciences 29 31%
Medicine and Dentistry 25 27%
Neuroscience 7 7%
Biochemistry, Genetics and Molecular Biology 4 4%
Engineering 4 4%
Other 13 14%
Unknown 12 13%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 March 2013.
All research outputs
#6,703,703
of 22,699,621 outputs
Outputs from Journal of Translational Medicine
#1,036
of 3,966 outputs
Outputs of similar age
#56,356
of 194,016 outputs
Outputs of similar age from Journal of Translational Medicine
#25
of 60 outputs
Altmetric has tracked 22,699,621 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 3,966 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.5. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 194,016 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 60 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.